THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024.

Amgen AMGN reported third-quarter 2024 adjusted ... up 88% from the year-ago period. Imdelltra (tarlatamab), approved for pre-treated advanced small cell lung cancer (ES-SCLC) in May 2024 ...

Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off.

Amgen AMGN reported third-quarter 2024 adjusted earnings of ... Lumakras/Lumykras recorded sales of $98 million in the quarter, up 88% from the year-ago period. Imdelltra (tarlatamab), approved for ...

Looking ahead, we remain confident that Amgen is well positioned to deliver ... and we have initiated a Phase Ib study evaluating subcutaneous tarlatamab in patients with second line or later ...

1 Department of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People’s Hospital of Changde City), Changde, China 2 Department of Electrocardiogram and ...

(RTTNews) - Amgen Inc. (AMGN) reported earnings for its third quarter that increased from the same period last year and beat the Street estimates. The company's bottom line came in at $2.83 ...

Lopez-Chavez highlights the FDA approval of tarlatamab-dlle (Imdelltra), a bispecific T-cell engager (BiTE), for the treatment of SCLC that has progressed on or after platinum-based chemotherapy, ...

He expects more visibility on Amgen’s launch plans for Imdelltra (tarlatamab) and growth strategy for key products like Tepezza and Krystexxa. JPMorgan’s Chris Schott also expects trial ...

Additionally, tarlatamab has shown efficacy in treating patients with brain metastases, further strengthening Amgen's position in the oncology market. Enbrel, one of Amgen's established products, ...